Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it the option to acquire Sail Biomedicines.
Johnson & Johnson has received FDA approval for its new surgical robot, Ottava, after years of development and significant investment. The approval raises questions about whether Ottava can compete with established rivals in the surgical robotics market.
Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it the option to acquire Sail Biomedicines.
Johnson & Johnson is cruising deeper into in vivo CAR-T waters, paying $785 million upfront to strike a deal that gives it the option to acquire Sail Biomedicines.
Johnson & Johnson announced collaboration with privately held Sail Biomedicines to develop CAR-T therapies for immune-mediated diseases, J&J said in a statement.
Johnson & Johnson said it would pay an estimated $5.5bn to resolve tens of thousands of lawsuits alleging its baby powder and other talc products.
Johnson & Johnson on Monday said it agreed to a $5.5 billion commitment to resolve litigation related to claims that its talc products caused ovarian cancer.
Johnson & Johnson said it would pay an estimated $5.5bn to resolve tens of thousands of lawsuits alleging its baby powder and other talc products.
Johnson & Johnson said it would pay an estimated $5.5bn to resolve tens of thousands of lawsuits alleging its baby powder and other talc products. Landmark deal covers about 76,000 claims and could end contentious, decade-long legal battle.
Johnson & Johnson said it would pay an estimated $5.5bn to resolve tens of thousands of lawsuits alleging its baby powder and other talc products cause cancer.
Johnson & Johnson said it would pay an estimated $5.5bn to resolve tens of thousands of lawsuits alleging its baby powder and other talc products cause cancer.
Johnson & Johnson said it would pay an estimated $5.5bn to resolve tens of thousands of lawsuits alleging its baby powder and other talc products cause cancer.
Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline
Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech Deals
Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines
Johnson & Johnson lowers 2026 profit forecast
Explainer: Can J&J finally put the talc litigation behind it?
Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer
Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits